Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
20 Décembre 2021 - 7:30AM
Business Wire
- Dr. Hervé Perron, Chief Scientific Officer, presented at “The
Lancet Summit: Presymptomatic Prevention and Treatment of
Neurodegenerative Diseases” additional results from the joint
NINDS/GeNeuro Amyotrophic lateral sclerosis (ALS) preclinical
research program
- Results confirm the efficacy of GeNeuro’s novel anti-HERV-K
monoclonal antibody against HERV-K-ENV mediated neurotoxicity
Regulatory News:
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company developing new treatments for
neurological and autoimmune diseases, announced today that its
Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the
“The Lancet Summit: Presymptomatic Prevention and Treatment of
Neurodegenerative Diseases” additional results from the preclinical
research program in Amyotrophic lateral sclerosis (ALS) developed
in partnership with the National Institute of Neurological
Disorders and Stroke (NINDS), part of the U.S. National Institutes
of Health (NIH).
“This joint NINDS/GeNeuro study has shown the specific and
efficient inhibition of HERV-K ENV neurotoxic effects from the
extracellular medium in vitro and in vivo, using GeNeuro’s anti
HERV-K K01 monoclonal antibody,” said Dr. Hervé Perron, Chief
Scientific Officer of GeNeuro.
“A new pathogenic mechanism has been unveiled and characterized,
and these results open new perspectives for a therapeutic
intervention against sporadic ALS,” said Dr. Avindra Nath,
Clinical Director at the National Institute of Neurological
Disorders and Stroke, who leads the joint NINDS/GeNeuro ALS
research program.
These results, following those presented by Dr. Avindra Nath at
the American Neurological Association (ANA) annual meeting on
October 17, 2021, show in vitro and in vivo the neurotoxic effects
specifically mediated by HERV-K ENV, a retroviral envelope protein
encoded by a pathogenic member of the HERV-K family of endogenous
human retroviruses (HERV-K ENV protein). More importantly, they
confirm the neutralizing effects of GeNeuro’s novel specific
monoclonal anti-HERV-K antibody.
As previously mentioned, GeNeuro’s preclinical development
program has enabled its anti-HERV-K ENV antibody to now be
humanized and ready to enter GMP manufacturing. The program could
start clinical trials as early as 2022.
"These results confirm the potentially key role of HERV-K ENV in
ALS and the potential of GeNeuro’s new antibody in this
indication," said Jesús Martin-Garcia, CEO of GeNeuro. "We
will now seek partnerships to bring this product to patients as
rapidly as possible."
The presentation is available on GeNeuro’s YouTube channel.
About ALS
Amyotrophic lateral sclerosis (ALS), often referred to as Lou
Gehrig’s disease or clinically as motor neuron disease, is a fatal,
rapidly progressive neurodegenerative disease characterized by loss
of motor neurons leading to progressive muscular paralysis. The
incidence of ALS is approximately 5 per 100,000 individuals in the
USA, 1-3 per 100,000 individuals worldwide, and is consistent
across diverse populations.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It owns rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Twitter YouTube LinkedIn
Disclaimer:
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words, such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211219005034/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
GeNeuro (EU:GNRO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
GeNeuro (EU:GNRO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024